Slc25a29-flox Mouse

Slc25a29, a member of the solute carrier family 25, is a mitochondrial transporter of basic amino acids, such as arginine, lysine, and homoarginine [3]. It plays a role in mitochondrial protein synthesis and amino acid degradation, and is involved in linking metabolic pathways occurring in the cytosol and mitochondrial matrix [3,4]. It is also associated with processes like the urea cycle and ornithine degradation pathway [4,6]. Genetic models, like knockout models, can be used to study its functions.

Knockout of SLC25A29 by CRISPR/Cas9 inhibited proliferation and migration of cancer cells both in vitro and in vivo, and led to an altered metabolic status with enhanced mitochondrial respiration and reduced glycolysis [2]. In lung adenocarcinoma, SLC25A29 was underexpressed and regulated endothelial cell phenotypes, with decreased expression leading to increased endothelial cell proliferation and migration and decreased apoptosis [1]. In prostate cancer, SLC25A29 is upregulated, correlating with metastatic features and serving as a high-risk prognostic factor, and may transactivate POLD1 via E2F1 [5]. In pancreatic cancer, the recruitment of numerous immune cells was negatively correlated with SLC25A29, and cisplatin sensitivity increased with its up-regulation [7].

In conclusion, Slc25a29 is essential for mitochondrial function and amino acid metabolism. Its knockout studies have revealed its significant roles in cancer-related processes such as cell proliferation, migration, metabolic regulation, and prognosis in various cancers including lung, prostate, and pancreatic cancers, providing insights into potential therapeutic strategies.